Shi-Yong Sun
Overview
Explore the profile of Shi-Yong Sun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
198
Citations
10273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chen Z, Vallega K, Wang D, Quan Z, Fan S, Wang Q, et al.
J Clin Invest
. 2024 Mar;
134(10).
PMID: 38451729
Development of effective strategies to manage the inevitable acquired resistance to osimertinib, a third-generation EGFR inhibitor for the treatment of EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC), is urgently needed....
12.
Sun S
Chin Med J Pulm Crit Care Med
. 2023 Aug;
1(1):3-10.
PMID: 37609474
Although the clinical efficacies of third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as osimertinib in the treatment of non-small cell lung cancer (NSCLC) with -activating mutations are...
13.
Zhao W, Yu D, Zhai Y, Sun S
Neoplasia
. 2023 May;
42:100908.
PMID: 37192591
The successful treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) with ALK tyrosine kinase inhibitors (ALK-TKIs) represents a promising targeted...
14.
Sun S
Front Med
. 2022 Sep;
16(5):701-713.
PMID: 36152124
A significant clinical challenge in lung cancer treatment is management of the inevitable acquired resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), such as osimertinib, which...
15.
Cai S, Hu T, Venkatesan M, Allam M, Schneider F, Ramalingam S, et al.
iScience
. 2022 Sep;
25(9):104980.
PMID: 36093051
Protein-protein interaction networks are altered in multi-gene dysregulations in many disorders. Image-based protein multiplexing sheds light on signaling pathways to dissect cell-to-cell heterogeneity, previously masked by the bulk assays. Herein,...
16.
Qian L, Vallega K, Yao W, Wang D, Zhai Y, He X, et al.
Mol Carcinog
. 2022 Sep;
61(11):1031-1042.
PMID: 36066010
Targeting the induction of apoptosis is a promising cancer therapeutic strategy with some clinical success. This study focused on evaluating the therapeutic efficacy of the novel Bcl-2/Bcl-X dual inhibitor, APG1252-M1...
17.
18.
Deng Y, Ma G, Vallega K, Wang D, Wang M, Wang C, et al.
Cancer Gene Ther
. 2022 May;
29(11):1801-1802.
PMID: 35538225
No abstract available.
19.
Yao W, Bai L, Wang S, Zhai Y, Sun S
Neoplasia
. 2022 Apr;
29:100798.
PMID: 35462114
New treatment options, such as targeted therapies, are urgently needed for the treatment of colorectal cancer (CRC), the third leading cause of cancer-related deaths worldwide. The current study focuses on...
20.
Deng Y, Ma G, Vallega K, Wang D, Wang M, Wang C, et al.
Cancer Gene Ther
. 2022 Apr;
29(11):1558-1569.
PMID: 35449204
SHP2, a protein tyrosine phosphatase, plays a critical role in fully activating oncogenic signaling pathways such as Ras/MAPK downstream of cell surface tyrosine receptors (e.g., EGFR), which are often activated...